Prospective Phycocompounds for Developing Therapeutics for Urinary Tract Infection

Curr Microbiol. 2023 Dec 8;81(1):35. doi: 10.1007/s00284-023-03535-2.

Abstract

Antibiotic resistance of bacteria is causing clinical and public health concerns that are challenging to treat. Infections are becoming more common in the present era, and patients admitted to hospitals often have drug-resistant bacteria that can spread nosocomial infections. Urinary tract infections (UTIs) are among the most common infectious diseases affecting all age groups. There has been an increase in the proportion of bacteria that are resistant to multiple drugs. Herein is a comprehensive update on UTI-associated diseases: cystitis, urethritis, acute urethral syndrome, pyelonephritis, and recurrent UTIs. Further emphasis on the global statistical incidence and recent advancement of the role of natural products in treating notorious infections are described. This updated compendium will inspire the development of novel phycocompounds as the prospective antibacterial candidate.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Cystitis* / drug therapy
  • Humans
  • Prospective Studies
  • Pyelonephritis* / drug therapy
  • Urinary Tract Infections* / drug therapy
  • Urinary Tract Infections* / microbiology

Substances

  • Anti-Bacterial Agents

Grants and funding